Amarin Adrift: Vascepa Label Expansion Doubtful After FDA Drops ANCHOR
This article was originally published in The Pink Sheet Daily
FDA’s decision not to reinstate a Special Protocol Assessment for the ANCHOR trial suggests a “complete response” letter on the related sNDA is not far behind.
You may also be interested in...
Agency makes clear that triglyceride levels are no longer an acceptable surrogate for reducing cardiovascular risk.
FDA is seeking public input on cross-cutting policy issues to bring before the senior-level group, which is also facing the challenge of reviewing dozens of “breakthrough therapy” designation requests relevant to CDER-regulated products.
US FDA’s expedited pathway remains alive and well in oncology, but ‘dangling’ indications may be subject to more regular public scrutiny going forward; negative votes for two of six indications reflected the influence of Oncology Center of Excellence director Richard Pazdur.